KAT6A and KAT7 Histone Acetyltransferase Complexes Are Molecular Dependencies and Therapeutic Targets in <i>NUP98</i> -Rearranged Acute Myeloid Leukemia
KAT6A and KAT7 associate with NUP98 FOs to drive leukemogenesis. Inhibition of their HAT activity is an effective therapeutic strategy in NUP98-r leukemias, including those resistant to menin inhibition. Moreover, combined KAT6A/7 and menin inhibition is synergistic, supporting clinical translation to improve outcomes for NUP98 FO-driven leukemias.
Authors
- Francisca N. de Luna Vitorino (ORCID: https://orcid.org/0000-0001-8543-2299)
- Cynthia Martucci (ORCID: https://orcid.org/0000-0001-6126-9458)
- Scott A. Armstrong (ORCID: https://orcid.org/0000-0002-9099-4728)
- Bright Arthur
- Daniela V. Wenge (ORCID: https://orcid.org/0000-0002-0064-9104)
- Richard W. Kriwacki (ORCID: https://orcid.org/0000-0002-9798-6018)
- Qingsong Gao (ORCID: https://orcid.org/0000-0002-9930-8499)
- Varsha Subramanyam
- Ali Khalighifar (ORCID: https://orcid.org/0000-0002-2949-8143)
- Pradyuamna Baviskar (ORCID: https://orcid.org/0000-0003-1110-5695)
- Ryan Hiltenbrand (ORCID: https://orcid.org/0000-0002-9267-9844)
- Jeffery M. Klco (ORCID: https://orcid.org/0000-0003-2961-6960)
- Vibhor Mishra (ORCID: https://orcid.org/0000-0002-4846-4790)
- Benjamin A. Garcia (ORCID: https://orcid.org/0000-0003-3596-4750)
- Charlie Hatton (ORCID: https://orcid.org/0000-0001-9903-4291)
- Pablo Portola
- Evangelia K. Papachristou (ORCID: https://orcid.org/0000-0002-5835-2055)
- Chun Shik Park (ORCID: https://orcid.org/0000-0002-4329-3953)
- David W. Baggett (ORCID: https://orcid.org/0000-0001-7437-1603)
- Charles Grenfell Mullighan (ORCID: https://orcid.org/0000-0002-1871-1850)
- Lingyun Long (ORCID: https://orcid.org/0000-0002-8064-832X)
- Alex Kentsis (ORCID: https://orcid.org/0000-0002-8063-9191)
- Bappaditya Chandra (ORCID: https://orcid.org/0000-0001-7595-937X)
- Ilaria Iacobucci (ORCID: https://orcid.org/0000-0003-2008-1365)
- Chandra Sekhar Reddy Chilamakuri
- Stanley Pounds (ORCID: https://orcid.org/0000-0002-9167-2114)
- Hongling Huang
- Nicole L. Michmerhuizen (ORCID: https://orcid.org/0000-0002-9960-5119)
- Sandi Radko-Juettner (ORCID: https://orcid.org/0000-0002-6969-5184)
- Hao Shi (ORCID: https://orcid.org/0000-0002-2796-629X)
- Danika Di Giacomo (ORCID: https://orcid.org/0000-0002-5558-7967)
- Laura J. Janke (ORCID: https://orcid.org/0000-0002-9871-6239)
- Hongbo Chi (ORCID: https://orcid.org/0000-0002-9997-2496)
- Emily Heikamp (ORCID: https://orcid.org/0000-0002-4591-4477)
- Huiyun Wu (ORCID: https://orcid.org/0000-0003-2728-4608)
- Yu Sun (ORCID: https://orcid.org/0009-0002-3927-1396)
- Peipei Zhou (ORCID: https://orcid.org/0000-0001-9033-2559)
- Clive S. D’Santos (ORCID: https://orcid.org/0000-0003-4592-0487)
- Joanna M. Gongora (ORCID: https://orcid.org/0009-0006-7613-8219)
- Masayuki Umeda (ORCID: https://orcid.org/0009-0002-5636-6602)
- Aurelie Claquin
- Josi Lott (ORCID: https://orcid.org/0009-0004-2504-8657)
Institutions
- St. Jude Children's Research Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- Xiamen University (CN)
- Washington University in St. Louis (US)
- Cornell University (US)
- University of Cambridge (GB)
- University of Perugia (IT)
- Cancer Research UK (GB)
- Kettering University (US)
- Cancer Research UK Cambridge Center (GB)
- Dana-Farber Cancer Institute (US)
- Alzheimer’s Research UK (GB)
- Dana-Farber Brigham Cancer Center (US)
Publication Details
- Journal
- Cancer Discovery
- Published
- 2025-06-19
- DOI
- https://doi.org/10.1158/2159-8290.cd-24-1772
- Citations
- 9
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 7.25
Funders
- Children's Cancer Research Fund
- Charles H. Hood Foundation
- Amgen
- Pfizer
- Leukemia and Lymphoma Society
- St. Jude Children's Research Hospital
- American Lebanese Syrian Associated Charities
- Break Through Cancer
- Syndax Pharmaceuticals
- European Commission
- National Institutes of Health
- National Cancer Institute
- Hyundai Hope On Wheels